Valuation: Noevir Holdings Co., Ltd.

Capitalization 146B 960M 928M 876M 773M 1.37B 83.31B 1.52B 10.43B 3.87B 34.61B 3.6B 3.53B P/E ratio 2025 *
18.4x
P/E ratio 2026 * 17.9x
Enterprise value 146B 960M 928M 876M 773M 1.37B 83.31B 1.52B 10.43B 3.87B 34.61B 3.6B 3.53B EV / Sales 2025 *
2.28x
EV / Sales 2026 * 2.23x
Free-Float
47.61%
Yield 2025 *
5.37%
Yield 2026 * 5.49%
More valuation ratios * Estimated data
Dynamic Chart
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2025 Nov. 08 CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024 23-11-07 CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024 23-08-07 CI
Noevir Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended March 31, 2023 23-05-10 CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2023 23-05-10 CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending March 2023 and for the Fiscal Year Ending September 30, 2023 23-02-07 CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending March 2023 and for the Fiscal Year Ending September 30, 2023 22-11-10 CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Period Ending September 2022 22-08-04 CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Period Ending September 2022 22-05-11 CI
Noevir Holdings Co., Ltd. Provides Earnings Guidance for the Six Months Ending March 2022 and for the Year Ending September 2022 22-02-08 CI
FACTBOX-Japanese companies opening COVID-19 vaccination sites amid slow national rollout 21-06-04 RE
An unknown buyer acquired a 12.9% stake in Noevir Holdings Co., Ltd. from Takashi Okura. 20-08-02 CI
Noevir Holdings Co., Ltd. Announces Consolidated Earnings Results for the Nine Months Ended June 30, 2019; Provides Earnings Guidance for the Fiscal Year Ending September 30, 2019 19-08-13 CI
More news
1 day+0.82%
1 week-3.36%
Current month-6.80%
1 month-7.80%
3 months-13.18%
6 months-19.19%
Current year-11.85%
More quotes
1 week
4 265.00
Extreme 4265
4 480.00
1 month
4 265.00
Extreme 4265
4 730.00
Current year
4 265.00
Extreme 4265
4 920.00
1 year
4 265.00
Extreme 4265
5 890.00
3 years
4 265.00
Extreme 4265
6 020.00
5 years
3 985.00
Extreme 3985
6 140.00
10 years
2 203.00
Extreme 2203
9 170.00
More quotes
Director TitleAgeSince
President 61 2011-03-21
Chief Tech/Sci/R&D Officer - 2019-12-04
Corporate Officer/Principal - 2023-11-27
Manager TitleAgeSince
Chairman 88 2011-03-21
Director/Board Member 67 2011-03-21
Director/Board Member 69 2011-03-21
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
+0.82%-3.36%-17.02%-15.72% 960M
-2.09%-3.30%-22.03%-5.35% 189B
-1.88%-3.48% - - 30.46B
+0.58%+6.78%+15.41%+26.29% 19.87B
-1.09%-0.16%-41.37%-60.93% 6.64B
-9.31%-11.91%-47.16%-34.12% 5.35B
-0.77%-8.04%-9.89%-33.37% 4.95B
-0.67%-0.54%-2.65%-3.21% 4.48B
+2.45%+0.60%-8.91%+43.73% 4.44B
+0.12%-0.83%-9.42%-16.31% 3.28B
Average -1.18%-2.11%-15.89%-11.00% 26.92B
Weighted average by Cap. -1.83%-1.64%-18.96%-4.73%
See all sector performances

Financials

2025 *2026 *
Net sales 64.1B 421M 407M 384M 339M 602M 36.53B 669M 4.57B 1.7B 15.18B 1.58B 1.55B 65.6B 431M 416M 393M 347M 616M 37.38B 684M 4.68B 1.74B 15.53B 1.61B 1.58B
Net income 7.95B 52.21M 50.46M 47.64M 42.03M 74.7M 4.53B 82.92M 567M 210M 1.88B 196M 192M 8.15B 53.53M 51.73M 48.84M 43.09M 76.58M 4.64B 85.01M 581M 216M 1.93B 201M 197M
Net Debt - -
More financial data * Estimated data
Logo Noevir Holdings Co., Ltd.
Noevir Holdings Co., Ltd. is a Japan-based company engaged in the manufacture and sale of cosmetics, toiletries, pharmaceuticals and foods, as well as the purchase and sale of cosmetic products. The Company operates in three business segments. The Cosmetics segment is engaged in the manufacture and sale of cosmetics and toiletries, as well as the purchase and sale of cosmetic products. The Pharmaceuticals and Foods segment is engaged in the manufacture and sale of general drugs and foods. The Others segment is engaged in the purchase and sale of apparels, body fashion, aircrafts and vessels, as well as air transportation business.
Employees
1,369
More about the company
Date Price Change Volume
25-02-12 4,315.00 ¥ +0.82% 27,200
25-02-10 4,280.00 ¥ -0.47% 48,900
25-02-07 4,300.00 ¥ -2.82% 73,700
25-02-06 4,425.00 ¥ -0.90% 69,100
25-02-05 4,465.00 ¥ -0.78% 41,700

Delayed Quote Japan Exchange, February 12, 2025 at 01:30 am EST

More quotes
Trading Rating
Investor Rating
ESG MSCI
BB
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4,280.00JPY
Average target price
4,530.00JPY
Spread / Average Target
+5.84%
Consensus

Quarterly revenue - Rate of surprise